Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2025)

Crinetics Pharmaceuticals has reported Free Cash Flow over the past 9 years, most recently at -$98.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$98.6 million for Q4 2025, down 47.2% from a year ago — trailing twelve months through Dec 2025 was -$383.7 million (down 66.55% YoY), and the annual figure for FY2025 was -$383.7 million, down 66.55%.
  • Free Cash Flow for Q4 2025 was -$98.6 million at Crinetics Pharmaceuticals, up from -$110.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CRNX hit a ceiling of -$13.5 million in Q1 2022 and a floor of -$110.7 million in Q3 2025.
  • Median Free Cash Flow over the past 5 years was -$43.4 million (2023), compared with a mean of -$49.7 million.
  • Biggest five-year swings in Free Cash Flow: surged 32.58% in 2022 and later tumbled 200.78% in 2023.
  • Crinetics Pharmaceuticals' Free Cash Flow stood at -$22.9 million in 2021, then plummeted by 60.59% to -$36.8 million in 2022, then decreased by 13.42% to -$41.7 million in 2023, then plummeted by 60.49% to -$67.0 million in 2024, then plummeted by 47.2% to -$98.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$98.6 million (Q4 2025), -$110.7 million (Q3 2025), and -$85.7 million (Q2 2025) per Business Quant data.